Samsung Bioepis Releases Q3 Biosimilar Market Trends Report
This biosimilars market report focuses on rising market complexity and recent activity, including two new approvals and four launches in Q2.
Samsung Bioepis released its Third Quarter 2025 United States Biosimilar Market Report today, providing an insight into industry pricing trends, dynamics and the Most-Favored-Nation (MFN) policy, according to a news release.
“When we first launched this report in Q2 2023, the US market had seen the approval of 40 biosimilars, with 28 products commercially launched,” Thomas Newcomer, vice president and head of U.S. commercial operations at Samsung Bioepis, said in the news release. “As of this tenth edition, the numbers have risen to 75 approvals and 53 launches, reflecting the market’s accelerating pace and growing complexity.”
In Q2, two biosimilars were approved by the FDA—Starjemza (ustekinumab), referencing Stelara (ustekinumab) and Jobevne (bevacizumab), referencing Avastin (bevacizumab). Four biosimilars were also launched—two in the denosumab market and two in the eculizumab market.
Read the slideshow above for the report highlights.
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Conversations with Perry and Friends: Saar Mahna, J.D., MBA
July 7th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the "Conversations with Perry and Friends" podcast. In this episode, Cohen speaks with Saar Mahna, J.D., MBA, CEO and founder of Banjo Health, an artificial intelligence company focused on prior authorization.
Listen
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
Aluminum in Vaccines Does Not Cause Autoimmune Disorders in Children, Study Shows
July 18th 2025Autoimmune diseases, such as vitiligo, celiac disease and rheumatoid arthritis, are not tied to aluminum exposure from vaccines, according to a nationwide cohort study of approximately 1.2 million children done in Denmark.
Read More
